Nature of the Event
Aurobindo Pharma Limited has issued notice for its 39th Annual General Meeting (AGM) pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The AGM will be held on Thursday, August 27, 2026 at 3:30 p.m. IST through Video Conferencing (VC) / Other Audio Visual Means (OAVM).
Key Dates and Logistics
- AGM Date: August 27, 2026 at 3:30 PM IST
- Cut-off date for e-voting: August 20, 2026
- Remote e-voting period: August 24, 2026 (9:00 a.m.) to August 26, 2026 (5:00 p.m.)
- Register of Members closure: August 26-27, 2026 (both days inclusive)
- Deemed venue: Corporate Office at Galaxy, Floors 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Hyderabad – 500 032
Ordinary Business Agenda
1. Adoption of Financial Statements: To receive, consider and adopt the Audited Standalone Financial Statements for FY ended March 31, 2026 with reports of Board of Directors and Statutory Auditor.
2. Consolidated Financial Statements: To receive, consider and adopt the Audited Consolidated Financial Statements for FY ended March 31, 2026 with Statutory Auditor's report.
3. Dividend Confirmation: To confirm interim dividend of ₹4.00 per equity share of ₹1 already paid for financial year 2025-26.
4. Director Re-appointment: Re-appointment of Mr. K. Nithyananda Reddy (DIN:01284195) who retires by rotation.
5. Director Re-appointment: Re-appointment of Dr. M. Madan Mohan Reddy (DIN:01284266) who retires by rotation.
Special Business Agenda
6. Appointment of Secretarial Auditor: Appointment of M/s. RPR & Associates, Practicing Company Secretaries, Hyderabad (represented by Mr. Y. Ravi Prasada Reddy, Proprietor with CP No. 5360) as Secretarial Auditor for 5 consecutive years from FY 2026-27 to FY 2030-31 at remuneration of ₹250,000 plus out-of-pocket expenses and applicable taxes for FY 2026-27.
Director Details
Mr. K. Nithyananda Reddy:
- Age: 68 years, Qualification: Postgraduate in Science
- Experience: Associated with company since initial days as promoter, versed in manufacturing technologies
- Remuneration: ₹54.69 million as Managing Director for year ended March 31, 2026
- Shareholding: 25,359,572 equity shares as on March 31, 2026
- First appointment: December 26, 1986
Dr. M. Madan Mohan Reddy:
- Qualification: Postgraduate in Science
- Experience: Over 30 years in pharmaceutical industry, associated with company since 2006
- Remuneration: ₹69.78 million as Executive Director for year ended March 31, 2026
- Shareholding: 2,010 equity shares as on March 31, 2026
- First appointment: September 18, 2006
Secretarial Auditor Change
M/s. MRR & Associates resigned as Secretarial Auditor effective May 21, 2026 due to health issues of its sole proprietor. The Board based on Audit Committee recommendation has appointed M/s. RPR & Associates as replacement.
Dividend Information
- Interim dividend of ₹4 per equity share already paid for FY 2025-26
- Unclaimed/unpaid first and second interim dividends for FY 2018-19 transferred to IEPF during the year
- Company will transfer first and second interim unpaid/unclaimed dividends for FY 2019-20 to IEPF in FY 2026-27
- Detailed schedule provided for transfer of unclaimed dividends from FY 2020-21 to FY 2025-26 to IEPF
Voting Procedures
- Remote e-voting through KFin Technologies Limited
- Individual demat account holders can vote through NSDL/CDSL platforms without additional registration
- Physical shareholders and non-individual shareholders receive login credentials from KFintech
- Facility for voting during AGM (Insta Poll) available for those who haven't voted remotely
- Scrutinizer: RPR & Associates represented by Mr. Y. Ravi Prasada Reddy
Shareholder Services
- KFin Technologies Limited appointed as Registrar and Transfer Agent
- Senior Citizens investor cell established at senior.citizen@kfintech.com
- Online Personal Verification (OPV) process introduced for digital identity verification
- WhatsApp service available at (91) 910 009 4099
- Investor Support Centre at https://ris.kfintech.com